GREEN LIFESCIENCE CO., LTD.
Financials
Valuation Metrics
GREEN LIFESCIENCE CO., LTD.'s Market Cap is ₩447B. At end of 2025 it was ₩580B. Ranked #1840 of 2,421 in KR market (top 76%), #1133 of 1,640 on KOSDAQ (top 69%), #194 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 44.70B KRW | KR#1,840/2,421 Sec#194/231 |
| Revenue | 58.57B KRW | KR#1,710/2,421 Sec#115/231 |
| Net Income | 7.36B KRW | KR#1,074/2,421 Sec#68/231 |
| Total Assets | 59.36B KRW | KR#2,114/2,421 Sec#185/231 |
| Net Assets | 44.85B KRW | KR#1,977/2,421 Sec#170/231 |
| Employees | 65 | KR#1,930/2,421 Sec#169/231 |
| Value | ||
| P/E | 6.08x | KR#462/2,421 Sec#19/231 |
| P/B | 1.00x | KR#1,456/2,421 Sec#92/231 |
| P/S | 0.76x | KR#1,208/2,421 Sec#63/231 |
| EV/EBITDA | 10.21x | KR#623/2,421 Sec#28/231 |
| FCF Yield | -1.11% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 16.40% | KR#260/2,421 Sec#16/231 |
| ROA | 12.39% | KR#176/2,421 Sec#14/231 |
| Op. Margin | 6.27% | KR#803/2,421 Sec#63/231 |
| Revenue Growth | 111.03% | KR#74/2,421 Sec#14/231 |
| Financial Health | ||
| Debt Ratio | 32.34% | KR#638/2,421 Sec#74/231 |
| Total Debt | 7.00B KRW | KR#1,722/2,421 Sec#159/231 |
| FCF | -495.7M KRW | KR#1,255/2,421 Sec#95/231 |
| Cash | 14.22B KRW | KR#1,471/2,421 Sec#118/231 |
| Current Ratio | 2.91x | KR#582/2,421 Sec#77/231 |
| Net Debt/EBITDA | -1.97x | KR#240/2,421 Sec#10/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -18.87% | KR#1,239/2,421 Sec#83/231 |
| 1M Return | 2.05% | KR#1,024/2,421 Sec#76/231 |
| From 52W High | -51.31% | KR#1,458/2,421 Sec#110/231 |
| 1Y MDD | -57.31% | KR#1,329/2,421 Sec#110/231 |
| Trading | ||
| Volume | 31,411 shares | KR#1,362/2,421 Sec#132/231 |
| Trading Value | 70.1M KRW | KR#1,708/2,421 Sec#174/231 |
| Foreign Own. | 2.46% | KR#1,475/2,421 Sec#140/231 |
| Per Share | ||
| EPS | 368 KRW | KR#1,095/2,421 Sec#76/231 |
| BPS | 2,243 KRW | KR#2,012/2,421 Sec#165/231 |
Company Info
Green Life Science, established in 2005 and headquartered in Yeosu-si, Jeollanam-do, is a specialized manufacturer of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, listed on the KOSDAQ market in 2009. The company pioneered the development of EDP-CL, a piperacillin-based antibiotic intermediate, in Korea, supplying it to global pharmaceutical companies, and its synthesis plant was the first in Korea to receive U.S. FDA approval. It produces various APIs and raw material intermediates, including DSC for HIV treatment and antibiotic intermediate AM19, while maintaining a quality management system compliant with cGMP standards.